InMed’s CEO, Mr. Eric A. Adams, presents at the Emerging Growth Conference. This virtual presentation was given on March 8th, 2023.
In the presentation, Mr. Adams presents a company overview. He talks about InMed’s rare cannabinoid pharmaceutical programs which includes a Phase 2 clinical trial investigating INM-755 cannabinol (CBN) cream for epidermolysis bullosa, a preclinical program using INM-088 CBN formulation for glaucoma, as well as the company’s most recently launched program in neurodegenerative disease. He shares the results from the study demonstrating how a specific rare cannabinoid inhibits or slows the progression of neurodegenerative diseases, such as Alzheimer’s, Parkinson’s and Huntington’s. Mr. Adams also speaks about the company’s manufacturing technologies and the rare cannabinoid products being sold by its subsidiary, BayMedica, to the health and wellness industry.